trending Market Intelligence /marketintelligence/en/news-insights/trending/9xf9wit_p73j3c61tpbqvq2 content esgSubNav
In This List

Forendo Pharma bags €4M funding from private equity firm

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Dealmaking slumps; rate hikes hammer gold; transaction banking revenues jump

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future


Forendo Pharma bags €4M funding from private equity firm

Forendo Pharma Ltd. received a €4 million funding from private equity firm Vesalius Biocapital III.

Vesalius Biocapital III Partners is a fund managed by Vesalius Biocapital Partners S.à r.l. and invests in later stage European life science companies in drug development, medtech, diagnostics and eHealth.

As part of the investment, Vesalius' Managing Partner Stéphane Verdood will join the Forendo Pharma board.

The funding enables Forendo, a portfolio company of Karolinska Development AB, to accelerate development of its women's health product candidates.

The company's lead program, known as FOR 6219, is being developed to treat endometriosis — a gynecological disorder that affects up to 10% of women in reproductive age.